Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI)
Ravina Kullar,1 Mai-Chi N Tran,2,3 Ellie JC Goldstein4,5 1Expert Stewardship, Inc., Newport Beach, CA, USA; 2Pharmacy Department, Keck Medical Center of USC, Los Angeles, CA, USA; 3Clinica Juan Pablo Medical Group, Los Angeles, CA, USA; 4R.M. Alden Research Laboratory, Santa Monica, CA, USA; 5David...
Saved in:
Main Authors: | Kullar R (Author), Tran MCN (Author), Goldstein EJC (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2020-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent <i>Clostridioides difficile</i> Infection (rCDI)
by: Sahil Khanna, et al.
Published: (2022) -
Clostridioides difficile infection (CDI) treatment outcomes and recurrence factor at a pediatric hospital
by: Martin Tuan Tran, et al.
Published: (2022) -
New advances in the treatment of Clostridium difficile infection (CDI)
by: Dennis D Hedge, et al.
Published: (2008) -
Reductions in inpatient fluoroquinolone use and postdischarge Clostridioides difficile infection (CDI) from a systemwide antimicrobial stewardship intervention
by: K. Ashley Jones, et al.
Published: (2021) -
The evaluation of Clostridium difficile infection (CDI) in a community hospital
by: Aju Daniel, et al.
Published: (2015)